Endometrium carcinoma in situ

Summary

Endometrium carcinoma in situ (MONDO:0003315) is a cancer. A subtype of endometrial carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	endometrium carcinoma in situ
Mondo ID	MONDO:0003315
DOID	DOID:5172
ICD-10-CM	D07.0
SNOMED CT	92582009
UMLS	C0346191
MedGen	87545
Anatomy (UBERON)	UBERON:0001295
Is cancer (heuristic)	yes

Also known as: carcinoma in situ of endometrium · endometrium in situ carcinoma · stage 0 endometrium carcinoma

Disease family

This is a subtype of endometrial carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer › uterine carcinoma › endometrial carcinoma › endometrium carcinoma in situ

Related subtypes (6): uterine corpus endometrial carcinoma, endometrial transitional cell carcinoma, endometrium adenocarcinoma, endometrial small cell carcinoma, endometrial squamous cell carcinoma, endometrial undifferentiated carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.